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We conducted a randomized, unblinded superiority trial to determine if modified 
laboratory reporting of positive urine cultures (UC) increased the appropriateness of antibiotic 
treatment among catheterized inpatients. Efficacy outcome was treatment appropriateness. 
Safety outcomes included adverse events, bacteremia, and death. Between November 2018 and 
June 2019, 100 consecutive positive UCs were randomized to the standard report (SR) (bacterial 
count, identification and susceptibility) or modified report (MR) (standardized comment). 
Exclusion criteria were pregnancy, current antibiotic treatment, intensive care unit (ICU) or 
urology admission, or neutropenia. Current antibiotic treatment was excluded because their use 
may affect culture interpretation. True diagnosis of catheter-associated urinary tract infection 
(CA-UTI) or catheter-associated asymptomatic bacteriuria (CA-ASB) was based on published 
criteria and prospective chart review. Patients were followed for 7 days after reporting. Of 543 
positive UC considered, 443 were excluded. The intention-to-treat (ITT) analysis included 100 
UCs, while per protocol (PP) included 90. CA-ASB was diagnosed in 75% of all urines and 60% of 
these cases were treated with antibiotics. All CA-UTI cases were treated. There was a trend 
towards increased appropriate treatment (untreated CA-ASB + treated CA-UTI) in the MR than 
the SR: 31/54 (57.4%) vs 23/46 (50.0%), (+7.4%, p=0.45, RR=1.15) by ITT analysis. PP analysis gave 
similar results. There were 4/54 (7.4%) deaths and 16/54 (29.6%) adverse events in the MR, and 
3/46 (6.5%) deaths and 19/46 (41.3%) adverse events in the SR (-11.7% adverse events, p=0.216). 






 We asked if modified reporting of positive urine cultures (UC) was effective in reducing 
inappropriate antibiotic treatment of catheterized hospital patients without causing harm. A MR 
indicated a positive UC, while a SR describes the identified bacteria, count, and potential 
medication(s) to treat the bacteria. Our conclusion depended on the proportion of appropriate 
antibiotic treatment based on diagnosis (e.g. treated catheter-associated urinary tract infection 
(CA-UTI) or untreated catheter-associated asymptomatic bacteriuria (CA-ASB)). Of 543 UCs 
considered, 443 were excluded based on our defined exclusion criteria (admitted to the intensive 
care unit or urology wards, pregnancy, using antibiotics at the time of urine collection, and low 
white blood cell (WBC) count). Of 100 UCs, 75% had CA-ASB, and 60% of these patients were 
inappropriately treated with antibiotics. The MR saw more appropriate treatment than the SR: 
31/54 (57.4%) vs 23/46 (50.0%), suggesting a trend towards improved antibiotic treatment 
following a MR. The safety outcomes for both groups were comparable, and  differences between 
them were not statistically significant (MR deaths and adverse events: 7.4% and 29.6%, 
respectively; SR deaths and adverse events: 6.5% and 41.3%, respectively). The MR trended 
towards more appropriate antibiotic treatment in comparison to the SR and may be safe. 
However,  larger studies are needed to make a better assessment. 
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Chapter 1: General Introduction 
 
1.1 Thesis Structure and Style 
 
This thesis will proceed following the manuscript style of presentation.  Figure 1: 
Pathogenesis of Urinary Tract Infection has been used in this body of work with permission from 
Springer Nature. 
 
1.2 Study Objective 
The purpose of this study is to determine if modified reporting of positive urine cultures 
collected from indwelling catheters improves the appropriateness of treatment for suspected 
CA-UTI and CA-ASB, without causing harm to patients. 
 
1.3 Chapter Summary 
The present chapter briefly outlines the style, structure, and flow of this thesis by outlining 
the main objective of each chapter. Chapter 2 intends to provide background information that 
will further the reader’s understanding of this study's objectives (Section 1.2). The background 
information includes:  the anatomical structure and function of the genitourinary system, the 
pathophysiology of urinary tract infection (UTI) and asymptomatic bacteriuria (ASB), as well as 
the indications and functions of indwelling catheterization. It also describes antimicrobial 
resistance (AMR) and the process of antimicrobial stewardship (AMS). Chapter 3 is a literature 
review describing previous antibiotic stewardship interventions involving the microbiology 
laboratory and/or changes to the ordering and reporting of urine cultures. Chapter 4 outlines the 
methodology of the study and includes: study design, study setting, urine culture assessment, 
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patient recruitment, population and inclusion criteria, the intervention and control groups, 
outcomes, and statistical analyses. It also discusses the randomization process, blinding, sample 
size, debriefing plan, and ethics approval information. Chapter 5 reports the study results 
including: participant flow, patient demographics, efficacy and safety outcomes. Chapter 6 is the 
discussion which provides an interpretation of the results, strengths and weaknesses of the study 
design, areas of improvement and future research goals. Chapter 7 concludes the study by 
summarizing the previously outlined objectives, outcome results, and their value to clinical 
practice and current antibiotic stewardship research. Chapter 8 and following appendices include 
references for all cited works, and additional information (i.e., study tools, approval forms, and 
permission forms) for reader reference, respectively.   
 
Chapter 2: Background Information and Study Rationale 
 
2.1 The Genitourinary System 
 
The genitourinary system is responsible for regulating body fluid balance and excretion of 
metabolic products through the kidney, ureter, urinary bladder, and urethra (Patton & 
Thibodeau, 2016). The upper urinary tract (UUT) consists of the kidneys and ureters, while the 
lower urinary tract (LUT) consists of the urethra and urinary bladder. During bladder 
catheterization, a urethral catheter is inserted transurethrally into the bladder (Schaeffer, 2019). 
Bladder catheterization is indicated for adults with urinary retention with or without bladder 
obstruction, when monitoring urine output, and during pharmacological therapy of the bladder 
(Schaeffer, 2019). In addition, bladder catheterization is used to manage hematuria associated 
with blood clots, immobilized patients, and open wounds in the perianal or sacral regions of 
incontinent patients (Schaeffer, 2019). 
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2.2 Urinary Tract Infection (UTI) 
Urinary tract infections occur when bacteria from the colon ascend the urethra and colonize 
the bladder (Mclellan, Hunstad, & Sciences, 2017). The bacteria (or uropathogens) adhere to the 
outermost epithelial layer of cells, eventually forming biofilm-like masses (Mclellan et al., 2017). 
These changes in the cellular environment trigger defense mechanisms in the urinary tract cells: 
inflammation, leukocytosis, the expulsion of uropathogen-containing lysosomes, and the 
exfoliation of infected epithelial cells into the urine (Mclellan et al., 2017) (Figure 1). Such defense 
mechanisms are initiated once the uropathogens have passed the urinary system’s front-line 
defenses including mucous production, urination, and the urinary microbiome (Spencer, 
Schwaderer, Becknell, Watson, & Hains, 2014). The most common uropathogen is Escherichia 
coli (E. coli), which accounts for 75-95% of uncomplicated UTIs, although Staphylococcus, 
Klebsiella, Enterobacter, Proteus, and Enterococcus genera are also common (Colgan et al., 2018; 
Mclellan et al., 2017). These pathogens colonize the bladder by adhering to the periurethral area 
and ascending to the urethra and bladder through pili, flagella, and recognition of adhesin 
proteins on bladder epithelium (Flores-Mireles, Walker, Caparon, & Hultgren, 2000). Along with 
other proteins and carbohydrates, pili and flagella are also involved in the production of a biofilm 
which protects the bacteria from antibiotic entry (Flores-Mireles et al., 2000). The process of 
catheterization induces an inflammatory response in the bladder that damages the mucosa, 
further providing the uropathogens with surfaces to which they can easily adhere (Lo, Nicolle, 
Classen, & Arias, 2008; Mclellan et al., 2017). This immune response causes an accumulation of 
fibrinogen on the catheter, which facilitates colonization and biofilm formation as many bacteria 
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express fibrinogen-binding proteins (Flores-Mireles et al., 2000). Considering this facilitated 
route, it is no surprise that over 75% of hospital-acquired UTIs occur in patients with a chronic 
indwelling catheter (CIC) (Centers for Disease Control and Prevention, 2015; Lo et al., 2008; 
Mclellan et al., 2017; Tambyah & Maki, 2000). Risk factors for an UTI include female sex, history 
of UTIs, sexual activity, vaginal infection, diabetes, and genetic susceptibility (Flores-Mireles et 
al., 2000). However, risk factors for CA-UTI include failure to maintain a closed drainage system, 
female sex, older age, and duration of catheter use (Lo et al., 2008). 
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Urinary tract infections can be classified based on location: cystitis occurs in the LUT, 
pyelonephritis occurs in the UUT (Colgan et al., 2018; Mazzulli, 2012; Mclellan et al., 2017). 
Bacterial infections can be classified as either ASB, uncomplicated UTI, or complicated UTI, 
though they may be difficult to distinguish. Asymptomatic bacteriuria occurs when there is a 
significant amount of bacteria present in the urinary tract as determined by laboratory results, 
but the patient does not experience any symptoms (Section 1.3)  (Mazzulli, 2012). Uncomplicated 
UTIs occur in functioning urinary tracts, while complicated UTIs are defined as UTIs associated 
with functionally or structurally abnormal urinary tracts, in the presence of a CIC, during 
transplantation of urinary structure(s), male sex, elderly age, infection by an antimicrobial 
resistant organisms, or pregnancy (Mazzulli, 2012). Finally, if a UTI is diagnosed in the presence 
of a urinary catheter, it is referred to as a CA-UTI (Tambyah & Maki, 2000). Given the variety of 
UTI definitions, correct diagnosis is critical as its indication guides the appropriate treatment.   
 
While CA-UTI patients can experience fever, pain, dysuria, frequent urination, and a change 
in urgency, these symptoms are non-specific and should not be the sole basis of diagnosis 
(Hooton et al., 2010). The presence of new costovertebral tenderness, rigors, or a new onset of 
delirium should also be considered when ordering an UC and subsequent treatment decisions 
(Hooton et al., 2010; Jaeger et al., 2019). Urinalysis via dipstick testing can be used to assess 
whether a UC is needed based on urine nitrites, white blood cells, and leukocyte esterase results 
(Centers for Disease Control and Prevention, 2015; Jaeger et al., 2019). There are three different 
ways in which a urine sample can be collected: midstream or clean catch, in/out catheterization, 
or indwelling catheterization (though not generally recommended). While the former two 
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methods are most common, 12% to 16% of acute care inpatients will have a catheter inserted 
during admission to hospital (Lo et al., 2008). The diagnostic criteria for CA-UTI defined by the 
Infection Diseases Society of America (IDSA) are as follows: 
1. Has an indwelling urethral, suprapubic, or intermittent catheter, 
2. Is positive for signs and symptoms compatible with UTI diagnosis and no other known 
source of infection (fever ≥ 38°C, suprapubic tenderness, costovertebral angle (CVA) 
pain or tenderness, urinary urgency, urinary frequency, or dysuria) 
3. Positive UC defined by growth of a minimum of 103 colony-forming units per milliliter 
(CFU/mL) of at least one organism in a single catheter urine specimen, or in a 
midstream urine specimen taken from a patient with a catheter removed within the 
last 48 hours (Hooton et al., 2010). 
 
It is common to begin antibiotic treatment at the same time that a urine is sent for culture 
and antimicrobial susceptibility results (“empiric” treatment). Treatment should be adjusted 
after UC results that identify significant growth of a uropathogen and associated susceptibility 
testing results are received (“targeted” treatment) (Mazzulli, 2012). Empiric treatment may be 
informed by the local antibiogram; In Newfoundland and Labrador, appropriate empiric 
treatment in females with an uncomplicated UTI could include nitrofurantoin PO, cephalexin PO, 
TMP/SMX PO, or ciprofloxacin PO for 3-5 days without the need for UC testing (Daley, 2018). 
Treatment guidelines for CA-UTI are poorly defined, as the catheterized population is 
heterogenous and ranges from healthy surgery patients to severely ill patients with many 
complications (Hooton et al., 2010). While both empiric and targeted treatment may be 
 8 
appropriate, targeted treatment is preferred because it limits unnecessary antibiotic use that 
could lead to antibiotic-resistant bacteria in the patient, as well as reduces unnecessary cost 
(Mazzulli, 2012).  
 
2.3 Asymptomatic Bacteriuria (ASB) 
Asymptomatic Bacteriuria is the presence of bacteria in the urinary tract in the absence of 
genitourinary signs or symptoms (Daley, 2018; Givler & Givler, 2019; Nicolle et al., 2005). It occurs 
more often in females than males and is typically caused by uropathogenic E. coli (Givler & Givler, 
2019; Nicolle et al., 2005). Increased age, diabetes, the presence of genitourinary abnormalities, 
and the presence of an indwelling catheter are additional risk factors (Claeys, Blanco, Morgan, 
Leekha, & Sullivan, 2019; Givler & Givler, 2019). In the absence of symptoms, the diagnosis of 
ASB requires two consecutive positive UCs for women or one positive UC for men (Claeys et al., 
2019). For inpatients with an indwelling urinary catheter, catheter-associated ASB (CA-ASB) can 
be diagnosed in asymptomatic catheterized patients based on a single positive UC, regardless of 
sex (Claeys et al., 2019).  
 
ASB is often inappropriately tested and treated with antibiotics; evidence has shown that 
treatment of ASB does not lead to reduction in mortality or pyelonephritis in most patients, with 
the exception of patients undergoing urological procedures expected to cause mucosal bleeding 
and perhaps pregnant women (Claeys et al., 2019; Givler & Givler, 2019; Nicolle et al., 2005; F. 
Smaill & Vasquez, 2019).  The use of antibiotic treatment for ASB during pregnancy to reduce 
pyelonephritis, low birthweight, and preterm birth, is based on low-quality evidence and it’s 
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indication varies across management recommendations (Nicolle et al., 2019; F. M. Smaill & 
Vazquez, 2015; F. Smaill & Vasquez, 2019). Treatment of ASB may cause harm, including adverse 
drug reactions, Clostridiodes difficile diarrhea, and an increased incidence of infections caused by 
antibiotic resistant uropathogens (Daley, Garcia, Inayatullah, Penney, & Boyd, 2018; Givler & 
Givler, 2019; Leis et al., 2014; Nicolle et al., 2005). 
 
2.4 Bladder Catheterization 
Urinary catheters are inserted in the urethra to access the urinary bladder, allowing urine to 
pass from the bladder to an external collection bag (Newman, 2002). Collection bags are fitted 
with an emptying spout for drainage; drainage is important in reducing the risk of antimicrobial 
infection for CIC patients (Lo et al., 2008). The increased risk of infection resulting from 
catheterization is due to the passage that the catheter provides for uropathogens, which is free 
of first- and second-line defenses of the urinary tract (Mclellan et al., 2017). 
 
2.5 Diagnosis of CA-UTI and CA-ASB 
Catheter-associated urinary tract infection and CA-ASB may be difficult to distinguish 
clinically because indwelling catheters themselves can cause urinary symptoms (e.g. urgency, 
frequency, and dysuria) and because the characteristics symptoms of a UTI are non-specific 
(Claeys et al., 2019; Lo et al., 2008). In addition, catheterized inpatients often have comorbidities 
that complicate diagnosis, and CA-ASB rate increases by 3-10% each day following 
catheterization, eventually affecting 100% of patients (Claeys et al., 2019). Urine culture alone 
cannot distinguish CA-ASB from CA-UTI as both conditions show significant growth, meaning the 
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diagnosis must be made clinically.  Risk factors for the treatment of ASB have been defined. 
(Daley et al., 2018). 
 
2.6 Antimicrobial Resistance (AMR) 
Antimicrobial resistance has long been identified as a significant threat to global health, 
stability, and national security (Bourdellon, Thilly, Fougnot, & Pulcini, 2017; World Health 
Organization, 2001). By definition, “antimicrobial resistance” encompasses the resistance of 
different microorganisms, including bacteria, viruses, fungi, and parasites, to the medications 
used to treat infections they cause (World Health Organization, 2001). The prevalence of drug-
resistant bacteria has been increasing globally over years in both inpatient and outpatient 
settings (Bourdellon et al., 2017; Tsuboi et al., 2017). This is a product of different factors but is 
largely due to misuse (encompassing both unnecessary and inappropriate usage) of antibiotics 
given for UTI and upper respiratory tract infections  (Bourdellon et al., 2017; Macvane, Hurst, & 
Steed, 2016). Extended-spectrum beta lactamase (ESBL) producing Enterobacteriaceae are one 
example of a very common cause of antibiotic-resistant UTIs, which must be treated with broad-
spectrum antibiotics (Choi & Yoo, 2019).  
 
In order to combat the immediate threat of AMR, antimicrobial stewardship (AMS) attempts 
to modify current practices in order to reduce the unnecessary use of antimicrobials and their 
resultant selective pressure favoring bacterial species.  
 
2.7 Antimicrobial Stewardship (AMS) 
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Antimicrobial stewardship is now considered an urgent need in infectious disease 
management (Tsuboi et al., 2017). Antimicrobial stewardship is formally defined as antibiotic 
treatment that results in the best clinical outcome, as well as a system-wide approach to 
promoting and monitoring proper antimicrobial usage to preserve the future effectiveness of 
antimicrobials (Nathwani et al., 2018). These stewardship initiatives are versatile in their 
applications and are implemented in different areas of the health care system. Initially starting 
with pharmacy and infectious disease clinicians, these they have expanded into the daily routine 
of public policy makers, nurses, physicians, and microbiologists (Bourdellon et al., 2017; Macvane 
et al., 2016). Inclusion of the microbiology lab has gained attention as it has the ability to 
influence treatment decisions before treatment is prescribed (Langford et al., 2019). Consultation 
with infectious disease physicians, educational interventions, guideline review, and restricted 
reporting are just some of the ways in which AMS can positively influence better patient 
outcomes by improving the appropriateness of antimicrobial therapy (Daley et al., 2018; 
Maclaggan et al., 2018; Macvane et al., 2016). With attention on UTIs, some AMS initiatives have 
focused on reducing the number of orders for UCs, improving the rate of appropriate treatment 





Chapter 3: Literature Review 
 
The Effectiveness of Antibiotic Stewardship Initiatives Implemented During the Ordering and 




 The process of performing an UC begins with urine collection by midstream, clean catch, 
an in/out catheter, or an indwelling catheter into a sterile container (Daley, 2018; Miller, 1985). 
Urine is transferred to culture media within 2 hours of collection at room temperature, or within 
24 hours if preserved (Daley, 2018; Miller, 1985). Bacterial growth is quantified in the 
microbiology lab using a fixed volume of urine and counting of bacterial colonies (colony forming 
units, CFU) (Daley, 2018; Miller, 1985). Bacterial identification and susceptibility results are 
reported if one or two types of bacteria are detected at greater than 10 x 103 CFU/mL, or if two 
or more types are detected with greater than 100 x 103 CFU/mL (Daley, 2018). Other patterns of 
growth are reported as mixed growth from specimen contamination, and identification and 
susceptibility testing results are not reported (Daley, 2018).  
 
 The overuse of antibiotics is a major global health concern that is in part the result of 
inappropriate treatment decisions, such as in response to a positive UC alone or inappropriate 
decisions to collect urine (Daley et al., 2018; Leis et al., 2014; Macvane et al., 2016; Nicolle et al., 
2005; Pharm et al., 2019; Stagg et al., 2018; World Health Organization, 2001). For example, ASB 
is frequently screened and treated unnecessarily; one of the most common explanations for 
treatment of ASB is reflexive treatment of the positive laboratory result rather than the 
treatment of presenting clinical features(Maclaggan et al., 2018)(Maclaggan et al., 2018) (Leis et 
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al., 2014; Maclaggan et al., 2018; Nicolle et al., 2005, 2019).  The unnecessary but frequent 
collection and ordering of UCs leads to the over-detection of ASB (Jaeger et al., 2019). Urine 
cultures should be reserved for patients with urinary symptoms, however some settings order 
routine pre-operative UC or add reflex UCs based on a positive urinalysis (Jaeger et al., 2019). 
Antimicrobial stewardship initiatives may target treatment of ASB or the ordering behaviour of 
UCs, and may come in many forms including audit-and-feedback, algorithms, and educational 
interventions (Daley et al., 2018; Leis et al., 2014). The microbiology laboratory report is rarely 
considered an AMS strategy, although “nudging” strategies within laboratory reports are gaining 
more traction (Daley et al., 2018; Langford et al., 2019; Pharm et al., 2019; Stagg et al., 2018). 
Nudging strategies are those that use strategic placement of “choice architecture” in reporting 
to influence prescriber behaviour and treatment decision without compromising their autonomy 
(Langford et al., 2019). Nudging highlights the role of the microbiology laboratory report in AMS. 
(Langford et al., 2019; Maclaggan et al., 2018; Macvane et al., 2016).  
 
This literature review aims to summarize previous AMS initiatives in the microbiology 
laboratory, and asks the following question: In what ways has the microbiology laboratory been 
integrated in AMS interventions that are aimed at reducing antibiotic usage through the ordering 
and processing and reporting of UCs? Furthermore, have these interventions been effective and 
is their implementation realistic in everyday practice? The purpose of this literature review is to 
determine whether AMS initiatives in the microbiology laboratory are worth pursuing based on 
previous findings, or if future efforts are better spent in a different setting. This question warrants 
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exploring because of the increasing risk posed by AMR, which will need to be managed by a set 
of diverse approaches to cover such a broad problem. 
 
3.2 Methods 
 The following string was searched in PubMed and Embase to yield 1 result: ’urinary tract 
infection' AND 'asymptomatic bacteriuria' AND 'indwelling catheter' AND 'antibiotic treatment' 
AND 'acute care inpatients'. Due to the low yield of this search, the MeSH string was expanded 
to the following and searched in Embase and PubMed: “laboratory AND intervention AND 
'antimicrobial stewardship' AND 'urinary tract infection'”. Papers were excluded if their 
intervention was inappropriate (unrelated to UC ordering, processing, or reporting) (n=10) or if 
they were review papers rather than papers describing experiments (n=2). The expanded search 
yielded 14 results, of which 12 were excluded (Figure 2). The PubMed search was done with the 
following filters to search results: clinical trial, full text, published in the last 10 years, and studies 
in humans. This yielded 2 results, one of which was included from the Embase search, and the 
other was excluded as an inappropriate intervention. Other articles were identified by searching 
the reference section of Daley et al. (2018) (Figure 2). From this resource, 2 additional 
publications were identified using the same inclusion and exclusion criteria as the database 
results (unrelated intervention n=2, review paper n=5). A final paper was obtained through 













3.3.1 Application of Interventions 
 
Six different stewardship interventions were used during the process of UC ordering, 
processing, and reporting. These interventions can be broadly categorized as (i) changes to the 
UC ordering process (2 papers) and (ii) reporting strategies (4 papers). 
 
(i) Changes to the UC Ordering Process 
 
The first study described was a before and after comparison of two-step ordering in an acute 
care urban hospital (Stagg et al., 2018). The control was the standard process, which involved 
urine collection and culture ordering in a single step by a nurse or physician (Stagg et al., 2018). 
The two steps of the intervention included “Step 1”: the ordering of a UC by a triage nurse, and 
“Step 2”: the submission of the specimen to the laboratory after assessment by a physician within 
48 hours (Stagg et al., 2018). Between Steps 1 and 2, the urine was held at the lab until the 
physician ordered Step 2, and in the meantime urinalysis was preformed (Stagg et al., 2018). The 
hypothesis was that two-step ordering would help reduce the over-ordering of UCs and 
treatment of ASB in relation to the numbers of UCs processed in the emergency department (ED) 
(Stagg et al., 2018). The second study was set in a tertiary care hospital emergency department 
that used reflex UC testing (Jaeger et al., 2019). The study design was not disclosed and there 
were insufficient details to infer. The order sheets for certain indications had UC pre-selected, 
regardless of the reflex to culture threshold based on screening results with urinalysis (Jaeger et 
al., 2019). For this intervention, the researchers modified the threshold from >3 WBC to >4 WBC 
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and un-selected the pre-selected UC order sets for indications that had the highest rate of 
negative culture (Jaeger et al., 2019). 
 
(ii)  Reporting Strategies 
 
Two papers used a modified reporting style (MR) for positive UCs. The MRs disclosed that the 
culture detected significant growth but withheld bacterial identification, bacterial counts, and 
susceptibility results (Daley et al., 2018; Leis et al., 2014). Leis et al. hypothesized that the pretest 
probability of UTIs would be low and this reporting style would show that physicians treat a 
positive UC rather than clinical status (Leis et al., 2014). Daley et al. hypothesized that the 
modified reporting among acute care inpatients would reduce inappropriate treatment of ASB 
without an increase in adverse events (Daley et al., 2018). Both of these interventions were 
tested in non-catheterized inpatients in acute care teaching hospitals, however Leis et al. used a 
proof-of-concept before/after study design, while Daley et al. used a unblinded parallel 
randomized control trial study design (Daley et al., 2018; Leis et al., 2014).  
 
A third study included this same reporting style in their overall intervention, which was a UTI 
management bundle also including education for nurses and prescribers and pharmacy 
prospective audit-and-feedback (Maclaggan et al., 2018). The authors hypothesized that this 
reporting style would decrease inappropriate treatment of ASB and the unintended 
consequences of unnecessary antimicrobial therapy, as well as improve appropriate collection of 
UCs and the selection and duration of antimicrobial therapy for UTI (Maclaggan et al., 2018). This 
was tested using a retrospective before and after study in a tertiary care hospital (Maclaggan et 
al., 2018). Lastly, the fourth publication altered UC results by selectively limiting the amount of 
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susceptibility results listed, to determine if this improved the appropriateness of antibiotic 
therapy selected, using a randomized control trial of case-vignettes (Bourdellon et al., 2017). As 
selective reporting is commonly used in practice today, this study is included to assess the quality 
of evidence supporting this reporting style. The case-vignettes disclosed identification and 
quantitative results unlike the previous interventions discussed.  
 
3.3.2 Major Findings of Stewardship Interventions 
 
(i) Changes to UC ordering processes 
 
 Stagg et al. reported that only 19.1% of all urines ordered in Step 1 had the second step 
ordered by physicians, the amount of ED visits requiring callback significantly decreased, and the 
turnaround time (TAT) for urinalysis significantly decreased by 21.01 minutes (Stagg et al., 2018). 
Furthermore, overall antimicrobial therapy and antibiotics prescribed for urinary indication 
significantly decreased for admitted ED patients (Stagg et al., 2018). In terms of urinalysis reflex 
to culture, Jaeger et al. also had favorable results, although the quality of this study was 
questionable. They reported a significant decrease of urinalysis reflex to UCs from a mean of 92 
to 49 per day, while the number of urinalysis without reflex to culture significantly increased from 
3 to 41 per day (Jaeger et al., 2019). The number of negative UCs per day significantly decreased 
by 54% (Jaeger et al., 2019). From the report, there was insufficient information to assess 
methods and the criteria used to update order sets and thresholds (Jaeger et al., 2019).  
 
 
(ii) Reporting Strategies 
 
 The findings of Leis et al. and Daley et al. were in agreement as both found that the MR 
had a higher proportion of appropriate treatment compared to standard reports for non-
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catheterized inpatients (Daley et al., 2018; Leis et al., 2014). Leis et al. reported a significant 
absolute risk reduction (ARR) of inappropriate treatment of 36% with no cases of untreated UTI, 
while Daley et al. reported ARR=27.3% with a higher proportion of untreated UTI in the standard 
arm compared to the modified arm (Daley et al., 2018; Leis et al., 2014). Similarly, MacLaggan et 
al. found that the MR included in the UTI management bundle lead to a significant decrease in 
inappropriate treatment of ASB (ARR=50.8%) (Maclaggan et al., 2018). They also found decreases 
in the average days of antimicrobial therapy (4.73 days to 1.05 days), the number of cultures 
collected without a doctor’s orders (-28.8%), and fluoroquinolone use (31.1% to 12.2% of empiric 
treatment, 30.5% to 18% of directed treatment), while ceftriaxone use in empiric treatment 
increased (9.5% to 36.6%) (Maclaggan et al., 2018).  
 
The findings of Bourdellon et al. also support the implementation of modifications to the 
standard UC report; results showed that limited susceptibility reports lead to higher rates of 
appropriate antibiotic selection in three out of four case-vignettes, while in the remaining case 
there was no difference between full and restricted results (Bourdellon et al., 2017). Of the case-
vignettes with higher appropriate antibiotic selection following the restricted reports, the 
percentage of appropriate antibiotic selection increased by 22.4% (Case 1), 67.5% (Case 3), and 




 These types of interventions are only as effective as the study results if they are 
implemented in the same manner and setting. In order for the interventions to be applied in 
every-day practice, they should not drastically change the workflow of those involved in UC 
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ordering and processing, and ideally, they should be well-received by microbiologists and 
physicians alike. It appears that the interventions were designed with this in mind, as the 
modified reporting of positive UCs required a simple change to the script that was sent to the 
electronic medical record. If this reporting style is used going forward, the lab would have to pay 
more attention to the ward from which the inpatient who submitted the sample was residing, as 
the ICU and obstetrics were not included in these trials (Daley et al., 2018; Leis et al., 2014; 
Maclaggan et al., 2018). This could likely be a simple fix, such as adding a reminder prompt in the 
laboratory information system for microbiology staff, but would still require a change in 
workflow. The limited reporting of susceptibility results has similar implications but would not 
cause a change in workflow for those involved. Furthermore, limited susceptibility had a 
favourable response from participating physicians, as over half of the participants considered 
limited reporting as an improvement to the quality of the antibiotic therapy they prescribed, and 
80.9% favoured its used in every day practice (Bourdellon et al., 2017). Out of all the interventions 
examined, it seems as though the urinalysis reflex to culture would require the least amount of 
change in workflow and employee demand, as it would be a matter of changing setting 
thresholds in an already automated process (Jaeger et al., 2019). The changes that would be 
required in order to implement each of the interventions described seems minimal and 
reasonable.  
 
It is notable that these interventions have all been tested recently with the earliest paper 
being published in 2014 (Leis et al., 2014). This suggests a growing focus on laboratory-based 
interventions which will influence and potentially improve their practicality, as they will  be 
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developed with new resources and consideration of previous experience. At this point the quality 
of the data produced is variable as it encompasses a combination of randomized control trials 
(RCTs) and before/after comparisons. Randomized control trials produce high quality evidence, 
but before/after comparisons create bias due to unmeasured system changes between the 
before and after periods.  (Murad, Noor, Alsawas, & Alahab, 2016; Thiese, 2014).   
 
3.5 Limitations and Safety 
None of the studies described were implemented in a hospital-wide setting (Bourdellon et al., 
2017; Daley et al., 2018; Jaeger et al., 2019; Leis et al., 2014; Maclaggan et al., 2018; Stagg et al., 
2018). Similarly, no studies included catheterized patients which makes the findings 
ungeneralizable to this study’s population. Some of these interventions were limited to adults 
(age ≥ 18), meaning that it cannot be assumed that they would work in pediatric or youth 
populations (Daley et al., 2018; Leis et al., 2014). Therefore, further investigation of AMS 
initiatives involving the microbiology lab and catheterized patients is warranted. Studies with 
interventions that required physicians to call for full reports had a low call-back rate, indicating 
that there was a risk of failure to treat UTIs (Daley et al., 2018; Leis et al., 2014; Maclaggan et al., 
2018). In one paper, there were two cases of untreated UTI, one of which progressed to 
bacteremia at 72 hours, however this was treated without any significant clinical sequalae 
(Maclaggan et al., 2018). Any adverse events in the Daley et al. and Leis et al. papers were 
individually investigated in their respective studies and deemed to be unrelated to the MR, 
indicating that the MR did not cause any harm to patients.  (Daley et al., 2018; Leis et al., 2014). 
Strategies that delay transportation of urine between the clinic and the laboratory beyond 2 
hours will be associated with changes in the UC results, causing a potential safety concern if urine 
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preservation is not used (Rabinovitch, Arzoumanian, Curcio, Dougherty, & Halim, 2009).  
Published CLSI criteria limit the time between collection and culture to 2 hours, due to false 
positivity of UC because of overgrowth during transportation (Bartlett, 2004).    
 
 The publication describing urinalysis with reflex to culture was very limited in its details: 
patient demographics, data collection method, and study design were not adequately described, 
so the strength and generalizability of their evidence could not be assessed (Jaeger et al., 2019). 
Regarding Bourdellon et al., the primary outcome was based on a general practitioner’s response 
to a hypothetical scenario, rather than real life. Theoretical case vignettes may produce a biased 
assessment of true behaviour in patient care;  while these cases were based on realistic scenarios, 
the results could not be directly applied to physician response in a real scenario. Furthermore, 
Bourdellon et al. described a randomized control trial case-vignette study, which includes two 
different study designs. Because of this, the results should have been reported separately: once 





 Laboratory AMS interventions in ordering and reporting of UCs have shown benefit 
without harm  (Bourdellon et al., 2017; Daley et al., 2018; Jaeger et al., 2019; Leis et al., 2014; 
Maclaggan et al., 2018; Stagg et al., 2018). All of the included studies reported reductions in 
inappropriate treatment or ordering of UCs in limited populations, however these strategies have 
not yet been widely implemented. Reported benefits imply that research involving AMS 
interventions in the microbiology lab and UC ordering should continue to be pursued. Further 
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studies should focus on the populations missing from the current data, such as catheterized 
patients, critically ill, pregnant and pediatric populations, or include entire inpatient populations. 
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CHAPTER 4: METHODS 
 
4.1 Study Design 
 
 This study was a prospective, superiority, parallel, unblinded randomized control trial 
comparing two different reporting styles for positive UCs using appropriate treatment following 
the report as the outcome. Urine cultures were obtained from inpatients at acute care hospitals 
in St. John’s, NL. Consecutive positive UCs were assessed for eligibility and those that met 
inclusion criteria were randomized into one of two arms, MR or SR, before culture results were 
released on the electronic health system (Meditech). Once randomized, results were released in 
Meditech following the format for the group they had been assigned to. Patients that provided 
the positive UCs were followed for 7 days to assess appropriateness of antimicrobial therapy and 
safety outcomes. For urines randomized to the MR group, physicians were able to obtain 
complete results via telephone 24 hours a day, 7 days a week. 
 
4.2 Study Setting 
 
 This study took place in St. John’s, Newfoundland and Labrador. Recruitment and data 
collection were performed at the Public Health Microbiology Laboratory (PHML), while patient 
assessment was completed at either the Health Sciences Center (HSC) or Saint Clare’s Mercy 
Hospitals (SCMH). 
 
4.3 UC Assessment 
 
 Urines were cultured using only MacConkey Agars, a selective and differential medium 
that supports growth of Gram-negative bacilli while inhibiting most Gram-positive bacteria 
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(Miller, 1985). Cultures were incubated for 24 hours at 35°C under ambient air, and interpreted 




 Following UC assessment, the microbiology technologist provided a tracking form 
(Appendix A) to the graduate students with the Accession Number (AN, a number that could refer 
back to the exact plate being assessed), and the Medical Care Plan number (MCP, a unique 
number that identifies patients and their history) for each positive UC to be assessed for 
eligibility. The graduate students assessed eligibility by searching the patient history of the 
inpatient associated with each sample using Meditech and inclusion/exclusion criteria (Section 
4.5). The appropriate ward was called before inclusion to confirm method of collection for the 
urine sample. Once confirmed, students randomized the sample to either the SR or MR according 
to the method described in Section 4.9. Students provided reporting assignment to the 
microbiologist by email using a secure server.   
 
4.5 Population and Inclusion Criteria 
 
 Urines included in this study were collected from patients who met the following inclusion 
criteria: 
i. Is at least 18 years of age  
ii. Is admitted to either HSC or SCMH  
iii. Is not pregnant (tested negative or not reproductive age) 
iv. Has a neutrophil count greater than 1.0 within 7 days of collection 
v. Is not taking antibiotics at the time of collection 
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vi. Provides a urine collected from an indwelling catheter present in the bladder for a 
minimum of 48 hours 
vii. Provides a urine that was not ordered by a urologist 
viii. Is not admitted to an intensive care unit (ICU) 
Patients taking antibiotics at the time of urine collection were excluded because current 
antibiotic usage may interfere with culture growth and interpretation (Wilson, Badarudeen, & 
Godwin, 2011). 
 
4.6 Intervention and Control Groups 
 
 The intervention in this study was a modified positive UC report that attempted to 
influence ordering behaviour and reduce inappropriate antibiotic treatment. The SR for a positive 
UC identifies the bacteria isolated, the quantity in CFU, and antibiotic susceptibility.  The MR 
informs the ordering physician or nurse that the culture is positive while withholding all other 
identifying, quantifying, and susceptibility information. It reads as follows: “This POSITIVE urine 
culture may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract 
infection is suspected clinically, please call the microbiology laboratory at ###-### for 
identification and susceptibility results”.  
 
4.7 Outcomes  
  
 Outcome results were determined by licensed physicians using prospective chart review. 
The primary efficacy outcome was the proportion of appropriate antibiotic treatment prescribed, 
based on published treatment guidelines. Cather-associated asymptomatic bacteriuria was 
distinguished from CA-UTI by the absence of documented symptoms. Inappropriate treatment 
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was any treatment for CA-ASB or no treatment for CA-UTI. The secondary efficacy outcome was 
the rate of physician calls to the lab requesting complete results (this outcome is limited to the 
MR arm). A licensed physician member of the research team determined and collected data for 
the safety outcomes: rate of bacteremia, number of deaths, adverse events at 72 hours, and 
patients meeting the Systemic Inflammatory Response Syndrome (SIRS) criteria. Adverse events 
were defined as meeting 2 or more of the criteria diagnostic of systemic inflammatory response 
syndrome (SIRS): body temperature > 38.3°C or < 36°C, heart rate > 90bpm, respiratory rate 
>20/min, leukocyte count > 12,000 or < 4,000, altered mental status, significant edema or 
positive fluid balance, and hyperglycemia in the absence of diabetes (Boka, 2018). Adverse events 
at 7 days were defined as the onset of any new signs or symptoms during the 7-day follow-up.  
 
4.8 Determination of Outcomes  
Two physicians (a physician specializing in infectious diseases and medical microbiology, 
and an internal medicine resident), assessed the efficacy and safety outcomes using prospective 
chart review. The patient care records written by the attending nurses and physicians were 
accessed using the local electronic medical records and paper charts. These records included 
patient care notes, laboratory work, medications, vital signs, etc. If there was dispute between 
physicians regarding the outcomes, the case was further investigated until a conclusion was 
made. Physicians were not blinded to each other’s outcome conclusions. The adverse events at 
7 days and bacteremia rates were assessed by both physicians. All deaths were investigated by 
the infectious disease and medical microbiology specialist and reported to ethics appropriately. 
 
4.9 Interim Analysis 
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 Interim analysis was performed when we recruited 50% of our sample size (N=50) to 




 A statistician at PHML randomized group assignment for recruited cultures using Excel for 
Office 365 (Version 1903). A list of numbers 1-100 (inclusive) were randomly assigned to “Normal 
Report” or “Modified Report” using this software, and the result for each number was printed 
and stuffed into individual and serially labelled envelopes with chronological study numbers. 
Graduate students responsible for recruitment were not involved in randomization and so were 
blinded to the assigned study arm until the culture was recruited and the according envelope was 
opened. Once a urine sample was recruited into the study, the according envelope was opened, 




 Blinding was difficult to enforce because investigators saw the report during the patient 
follow up. For this reason, investigators were not blinded to allocation. 
 
 
4.12 Sample Size 
 Sample size was calculated based on a previously observed absolute difference of +23%  
appropriateness in the modified arm compared to the standard arm and an expected rate of 
inappropriate treatment of 45% and 15% in the standard and modified reporting arms, 
respectively (Daley et al., 2018). Using a=0.05 and b=0.20, the required sample size for this study 
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was calculated to be N=90 per arm. An additional 10 samples were added to account for missing 
data/loss to follow-up, for a total sample size of N=100 per arm. 
 
4.12 Statistical Methods 
 Intention-to-treat (ITT) analysis was used to analyze all specimens randomized into the 
study. In addition, per-protocol (PP) analysis was used to analyze the specimens that followed 
protocol. Interim analysis was performed when 50% of our sample size was recruited, to assess 
safety outcomes only. There were no preliminary stopping rules. Outcomes were analyzed using 
a 2-sided Pearson Chi-squared test using SPSS version 26.0 software (IBM, Markham, ON). 
Fisher’s Exact Test was used to assess the significance of differences in proportions between 
groups. Confidence intervals for bacteremia rate in the standard arm was assess with a one-sided 
97.5 confidence interval based on the results from a confidence interval for a proportion 
calculator (Kohn & Senyak, 2020). Two-sided 95% confidence intervals were used to assess the 




The study was approved by the Health Research Ethics Board for Clinical Trials on July 
16, 2018 (file 2018.098). The requirement for patient and physician consent was waived, 
because awareness of the study may have influenced treatment decisions.   
  
 
4.15 Debriefing Plan for Physicians and Patients 
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 Physicians were informed of the study prior to initiation and debriefed about the study 
following completion. Physicians and residents of inpatients at HSC and SCMH received an email 
inviting them to a debrief session with the principal investigator. Physicians and residents were 
provided with study results and given the option to withdraw their patient data if desired. 
Patients who submitted an UC that was included in the study were sent a letter that explained 





CHAPTER 5: RESULTS 
 
5.1 Participant Flow 
 
Recruitment began on November 6th, 2018 and was completed on June 5th, 2019. During 
these 9 months, 543 samples were assessed for eligibility and 443 (81.6%) were excluded because 
they did not meet inclusion criteria. Intention to treat analysis included 100 samples; 46 samples 
were randomized to the SR, and 54 samples were randomized to MR. Of these 100, 10 samples 
were excluded post-randomization leaving 90 samples to be included in the per protocol (PP) 
analysis (SR N=43, MR N=47) (Figure 3). In the SR, the losses to follow-up were due to death 
before 72 hours (n=3), discharge before 72 hours (n=6), and lab error (n=2). In the MR, the losses 
to follow-up were due to death before 72 hours (n=3), discharge before 72 hours (n=6), 
recruitment errors (n=2), and lab errors (n=5). Lab error occurred when the UC result was 
changed by the lab after the culture had already been randomized or when the report released 
did not follow randomization. Recruitment error occurred when the sample was recruited into 




Figure 3: Participant Flow 
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5.2 Patient Demographics 
 
 Demographics were comparable between SR and MR groups. The groups were 
comparable in mean age ± SD (ITT-SR 73.6 ± 13.9 years, ITT-MR 71.4 ± 13.1 years), proportion of 
CA-UTI (ITT-SR 26.1%, ITT-MR 22.2%), and proportion of CA-ASB (ITT-SR 71.4%, ITT-MR 77.8%). 
There was a lower proportion of females in the SR than the MR (ITT-SR 39.1%, ITT-MR 51.9%).  
The proportion of CA-UTI was higher in the SR (ITT-SR 26.1%, ITT-MR 22.2%) while the proportion 
of CA-ASB was lower in the SR (ITT-SR 71.7%, ITT-MR 77.8%) (Table 1). 
 
Table 1: Patient Demographics 
 








































* P value (Fisher’s Exact Test) 
** P value (two-sided 95% confidence interval) 
 
5.3 Efficacy Outcomes 
 
 Treatment appropriateness was calculated based on the sum of the proportion of 
patients with treated UTI and untreated ASB. For both ITT and PP analysis, appropriate treatment 
occurred more often with the MR than in the SR. Using ITT analysis, the proportion of appropriate 
treatment in the modified arm was 57.4%, while appropriateness in the standard arm was lower 
at 50.0% (Table 2). This produced an absolute increase of 7.4% and relative risk RR=1.15 
(0.746,1.765) (Table 2). Using PP analysis, the proportion of appropriate treatment in the 
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modified arm was 61.4%, while appropriateness in the standard arm was lower at 53.5% (Table 
2). This produced an absolute increase of 8.2% and relative risk RR=0.867 (0.606,1.240) (Table 2). 
 
Table 2: Proportion of Appropriate Treatment  
 
  Absolute Risk 
Reduction 
Relative Risk (95% CI) 
SR MR P value* 
ITT 23/46 (50.0%) 31/54 (57.4%) 0.547 7.4% 1.15 (0.746, 1.765) 
PP 23/43 (53.5%) 29/47 (61.7%) 0.523 8.2% 0.867 (0.606, 1.240) 
*P value for Fisher’s Exact Test 
 
The secondary efficacy outcome was the proportion of physicians that called for the 
complete report after receiving the MR.  Using ITT analysis, a full report was requested in 33.3% 
cases, and in 36.1% of cases in PP analysis. The majority of the calls were made by physicians or 
residents, followed by nurses and pharmacists (Table 5).  
 
Treatment timing trended towards less treatment at the time of urine collection, (32/70, 
45.7%) and towards more treatment after receiving the UC report (38/70, 54.3%) (Table 3). Of 
all antibiotics given, ciprofloxacin (MR-14.8%, SR-26.1%) nitrofurantoin (MR-13.0%, SR-15.2%), 
and ceftriaxone (MR-9.3%, SR-9.3%) were most common in both arms. All antibiotic treatments 
used can be found in Appendix B (Table 10). Treatment duration was variable but shorter in the 






Table 3: Antibiotic Treatment Timing 











SR 12 (26.1%) 15 (32.6%) 9 (19.6%) 10 (21.7%) 46 (100%) 
MR 18 (33.3%) 17 (31.5%) 15 (27.8%) 4 (7.4%) 54 (100%) 
Total 30 32 24 14 100 











SR 12 (27.9%) 13 (30.2%) 9 (20.9%) 9 (20.9%) 43 (100%) 
MR 16 (34.0%) 15 (31.9%) 13 (27.7%) 3 (6.4%) 47 (100%) 
Total 28 28 22 12 90 
 
Table 4: Common Antibiotic Treatment Regimen 
Antibiotics Used 
 Ciprofloxacin Nitrofurantoin Ceftriaxone 
SR 12/46 (26.1%) 17/46 (15.2%) 6/46 (13.0%) 
MR 8/54 (14.8%) 7/54 (13.0%) 5/54 (9.3%) 
Average Treatment Duration 
 SR (mean ± SD), (range) MR (mean ± SD) P-value* 
ITT 4.2 ± 4.4 days, (1, 21) 3.6 ± 3.6 days, (1, 13) 0.455 
PP 4.3 ± 4.5 days, (1, 21) 3.5 ± 3.5 days, (1, 12) 0.347 
*P value (two-sided 95% confidence interval) 
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Table 5: Calls Received Requesting Standard Report 
  
 Healthcare Worker Total 
 Physician/Resident Nurse Pharmacist 
ITT 10 7 1 18/54 (33.3%) 
PP 9 7 1 17/47 (36.1%) 
 
5.4 Safety  
 
 There were 3 deaths in the SR arm and 4 deaths in the MR arm (Table 7). Each death was 
investigated independently by a physician and none were found to be related to the MR (Table 
7).  There were no bacteremias in the SR arm and 3 bacteremias in the MR arm.  Each bacteremia 
was investigated independently by a physician and none were found to be related to the MR.  All 
positive blood cultures were collected at the time of UC collection, meaning that no new 
bacteremias occurred during patient follow-up (Table 8). The occurrence of 2 or more SIRS 
criteria at 72 hours follow-up was more frequent in the MR compared to the SR (ITT-MR 24.1%, 
ITT-SR 17.4%, p=0.414). This was consistent in the PP analysis, PP-MR 22.9% and PP-SR 18.6%, 
p=0.577 (Table 6). Adverse events at 7 days were more common in the SR (19/46, 95% CI 
(0.270,0.568) versus 16/54, 95% CI (0.180,0.436) in the MR). There was no significant difference 





Table 6: Safety  
 
Deaths 
 Standard (95% CI) Modified (95% CI) P value* 
ITT 3/46 (6.5%) 
 
4/54 (7.4%) 0.863 
PP 2/43 (4.7%) 3/47 (6.4%) 0.720 
Bacteremias 











SIRS at 72 Hours*** 























*P value (Fisher’s Exact Test) 
** Indicates one-sided 97.5% confidence interval. 
***SIRS criteria met if patient exhibited 2 or more of body temperature > 38.3°C or < 36°C, 
pulse >90/min, respirations >20/min, WBC count >12,000 or <4,000, altered mental status, 
significant edema or positive fluid, or hyperglycemia without diabetes.  
  
 38 
Table 7: Deaths 
 
Study Number 2 12 17 40* 76 80 81 
Study Arm SR MR MR MR SR MR SR 
Age 83 85 73 77 83 74 83 









































































































Nov 06, 2018 
Nov 18, 






2018 Mar 20, 2018 













N/A Sepsis Pneumonia N/A N/A N/A N/A 
Diagnosis at 



































Renal failure CHF 
Was death 
related to the 
intervention? 
No No No No No No No 
 
* Excluded from PP analysis. 
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Table 8: Bacteremias 
 
Study Number 10 23 88 
Study Arm MR MR MR 
Age 80 70 85 
Sex M M M 
Reason for Admission Urosepsis UTI cap Urosepsis 
Comorbidities Urethral stricture, 
recurrent UTI, COPD, 











Reason for Collecting 
UC Fever Weakness/unwell Urosepsis 
Date for Complete UC 
Result: Bacterial ID Nov. 16, 2018 P. aeruginosa 
Nov 26, 2018, 
Restricted report 
Apr. 15, 2018 
E. faecalis, P. 
aeruginosa 
Reason for Collecting 
Blood Culture Fever Weakness/unwell Shortness of breath 
Date for Complete 
Blood Culture Result: 
Bacterial ID 
Nov. 20, 2018 
P. aeruginosa 
Nov. 27, 2018 
MRSA 
Apr. 15, 2018 
E. faecalis 






Pip/tazo IV, Ampicillin 
IV, Cefuroxime PO 
Presumed Cause of 
Bacteremia Urosepsis Urosepsis Urosepsis 
Was bacteremia 
related to the 
intervention? 





Table 9: Adverse Events at 7 Days 
 
Adverse Event MR SR 
Acute Kidney Injury 1 0 
Anxiety 0 1 
Aspiration Pneumonia 0 1 
Auditory Hallucinations 0 1 
Candidemia 0 1 
Chest Pain 1 0 
Confusion 0 1 
Constipation 0 1 
Decreased level of 
consciousness 0 1 
Decreased white blood cell  0 1 
Delirium 1 1 
Diarrhea 1 0 
Dizziness 0 1 
Edema 0 1 
Fall 0 1 
Fever 1 0 
Fluid Overload 0 1 
Gross Hematuria 0 1 
Hypokalemia 1 1 
Increased liver enzymes 0 1 
Increased penile discharge 0 1 
Respiratory Secretions 1 0 
Sacral tear 1 0 
Shortness of Breath 1 1 
Stool Impaction 0 1 
Suicidality 1 0 
Suprapubic Tenderness 1 0 
Tachycardia 1 0 




CHAPTER 6: DISCUSSION 
 
6.1 Patient Flow and Randomization 
  
 Because the study only included catheterized patients, many urine specimens were 
excluded. Non-catheterized urine specimens were analyzed in a previous study (Daley et al., 
2018). Demographics were evenly distributed between groups with the exception of female sex. 
Female sex is a risk factor for UTI and ASB, but this would not bias our analysis because all patients 
were catheterized, and catheterization bypasses the female genital anatomy which predisposes 
to bacterial penetration of the bladder (Hooton et al., 2010; Letica-Kriegel et al., 2019).  
 
 Any losses to follow-up were a result of discharge or death within 7 days. However, the 
retention for assessing overall safety outcomes was high as most patients remained in the study 
for at least 72 hours, or were included in the death analysis (Figure 4). The MR observed two 
incidences of recruitment error that violated inclusion criteria. One of these urines were ordered 
by a urologist, however that was not known at the time of inclusion because this physician was 
not included on the list of urologists provided to the graduate students for recruitment. Following 
this, the list was revised to ensure that all urologists were listed. The second recruitment error 
was due to a patient being on antibiotics at the time of collection. This error occurred because 
the antibiotic treatment was not appropriately documented in the online medical record used to 
assess medication status and was found elsewhere after randomization.  Based on the ITT and 





6.2 Efficacy outcomes 
 The MR appears to have a positive trend towards more appropriate treatment as 
indicated by the higher proportion of appropriate treatment compared to the standard arm. 
However, the proportion of inappropriate treatment in both arms was high (22/46 47.8% SR, 
23/54 42.6% MR). This confirms that physicians continue to treat positive UCs without 
considering the patient’s symptom history, as seen in a previous study (Daley et al., 2018). In 
both arms, the proportion of CA-ASB was higher than CA-UTI, indicating that the majority of 
included UCs should not have been ordered. The rate of CA-ASB observed (75.0%) is higher than 
in the previous study done in non-catheterized inpatients (69.1%), confirming that the over-
ordering of UCs is a significant issue in acute care and a desirable target for future stewardship 
initiatives (Daley et al., 2018; Jaeger et al., 2019; Redwood et al., 2018).  ASB treatment rate was 
similar in the catheterized and non-catheterized population, however the proportion of 
inappropriate treatment in the MR was much higher in the catheterized population (51.1% 
compared to 25.7% in non-catheterized) (Daley et al., 2018). This is likely due to the increased 
risk of CA-UTI posed by catheterization and the difficulty in differentiating CA-ASB from CA-UTI 
in these patients, compared to non-catheterized patients (Lo et al., 2014). 
 
Twenty-eight treatments out of ninety  (31.1%) were given at the time of urine collection 
in both arms, suggesting that a MR intervention occurs too late to influence these treatment 
decisions. However, the MR is a suitable intervention when treatment is given after identification 
and susceptibility reporting, which cumulatively accounted for the majority of treatment 
decisions in both arms (ITT-MR: 19/54 (35.2%), ITT-SR: 19/46 (41.3%)). Treatment duration was 
 43 
extremely variable in both groups and averaged 3.6 days in the MR and 4.2 days in the SR 
(range=(1,13) days in MR, range=(1,21) days in SR). Comparison of treatment duration was done 
to observe if physicians seemed to reassess antimicrobial treatment when given the MR as 
opposed to the SR. While the average treatment duration observed may seem short compared 
to the suggested 7-14 days stated in guidelines, this may be appropriate as physicians should 
reassess the antimicrobial treatment given at 3 days with the opportunity to change or terminate 
therapy (Spectrum Mobile Health Inc., 2018). As it was not determined during our investigations, 
future studies should examine the ordering physician’s rationale for their treatment decisions. 
This would provide valuable information that can expand our knowledge of the interaction 
between the use of evidence-based guidelines and the surrounding medical culture, and the 
resultant effect on treatment decisions. 
 
The existing medical culture in acute care settings facilitates the inappropriate treatment 
of CA-ASB seen in our study. The over-ordering and treatment of results rather than symptoms, 
as well as the increased risk of developing CA-UTI in catheterized patients may have influenced a 
clinical bias towards treatment.  This appears to be supported by our findings that only 37% of 
MRs called the laboratory for complete results and that the proportion of inappropriate 
treatment remained high in the MR arm. 
 
6.3 Safety outcomes 
 
Our results support previous findings that MR is a safe intervention in acute care settings, 
however because our data did not result in significant findings, we cannot confidently say that 
the MR is fully safe in the catheterized population. There were no cases of untreated UTI, 
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meaning that no cases were allowed to progress to pyelonephritis due to the MR. The MR was 
also safer than the standard report based on the lower proportion of cumulative adverse events, 
and safe in that no cases of death or bacteremia were associated with the MR. However, the 
proportion of patients that met SIRS criteria was higher in the MR arm. SIRS criteria are non-
specific and may be caused by underlying illness, not only CA-UTI (Boka, 2018). The implication 
of other sources of SIRS is possible as the majority of patients submitting positive UCs were 
seniors and on other medications at the time of admission (Boka, 2018). Regardless, a higher rate 
of SIRS in the MR is concerning, and if the modified report is to be used in clinical practice, 
patients should continue to be monitored for SIRS criteria and investigated appropriately. 
 
 
6.4 Strengths and Limitations 
 
 MR is a useful and effective AMS intervention because it has the ability to prevent 
inappropriate treatment and is extremely practical (Daley et al., 2018; Leis et al., 2014). Based on 
current findings, the realistic implementation of a MR would require institution-specific 
guidelines as to which patients and wards would be eligible. The actual change and 
implementation of MR would not require excessive additional work for hospital and microbiology 
staff, as a simple change in report script would be the main requirement. Our study design was a 
randomized controlled trial which reduced the risk of confounders presented by other ongoing 
AMS initiatives (Langford et al., 2019).  
 
The main limitation in this study was the extensive inclusion/exclusion criteria which 
diminished the generalizability of our findings. These criteria also limit the practicality of the 
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intervention, as it would be very difficult for the microbiology laboratory to assess eligibility with 
the current urine culture collection, processing, and reporting protocol. Furthermore, the 
diagnosis of CA-UTI and CA-ASB in our study are based on chart review; inconsistencies in 
charting may have led to missing information, possibly creating a bias towards the diagnosis of 
CA-ASB. Incomplete records also caused difficulty in confirming the method of collection of each 
urine, despite calling the ward to discuss with nursing. As this study repeated an intervention 
from a previous study showing very significant benefit, the calculated sample size used was done 
using an expected amount of appropriate treatment from the previous study (Daley et al., 2018). 
This unfortunately led to an underpowered study due to a smaller observed effect size compared 
to the previous study, and indicates that this study may not have been sufficiently powered to 
best analyze adverse events.  Participation from the urology department would have been 
beneficial as this department treats many CA-UTIs and has many patients with a CIC.  
 
With these limitations in mind and the lack of evidence in laboratory AMS interventions, 
future studies should be more inclusive where possible and have a larger sample size. Future 
research should focus on interventions at a different point in the process of inpatient UTI care, 
such as before ordering a urine culture or before giving treatment, as well as consider the bias 




CHAPTER 7.0: Conclusion 
 
 We measured the impact of MR on treatment appropriateness for CA-UTI and CA-ASB. 
We found that CA-ASB was common and often inappropriately treated. Our findings were 
clinically significant as they demonstrated the MR to have a higher proportion of appropriate 
treatment compared to the SR, with similar rates of adverse events and no association with 
bacteremia or death. It is noteworthy however that the MR did have a higher proportion of 
patients meeting SIRS criteria compared to the standard report, which is concerning and should 
be taken into consideration for future testing or implementation of a MR. These findings agree 
with previous research (Daley et al., 2018; Leis et al., 2014). We have learned that a MR is not as 
effective in a catheterized population compared to a non-catheterized population. The 
catheterized population receives treatment much more frequently, likely due to their unique risk 
factors for bacterial infection that are absent in non-catheterized patients.   
 
Antimicrobial resistance is in part a societal issue for which the behaviour around 
antibiotic treatment needs to change. Future research can support these goals by testing 
interventions that occur at different points in patient care and are practical. Furthermore, 
interventions should be as generalizable to a hospital-wide setting where possible. The MR 
should continue to be investigated, as it is known to influence treatment, is practical, and 
requires more data on its safety in the catheterized population. A better knowledge of the MR’s 
safety outcomes can inform the implementation of its use in everyday practice. The MR can also 
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Appendix A: Study Forms 
 




CONFIDENTIAL Restricted Reporting of Urine Culture Research Study Case Report Form Jan 20, 2016 INPATIENT
Instructions: Complete one CRF for every consecutive significant growth urine culture during the study period
SPECIMEN INCLUSION CRITERIA RESULT RELEASE (Study lab results released by phone not Meditech)
Y N Age ≥ 18 
Y N Pregnant Did physician call the Lab for complete result?  Y N
Y N Long-Term Care Date physician called: D D M M Y Y Y Y
Y N Currently on Antibiotics Time physician called: H H H H
Y N Adm to hospital other than HSC or SCM Date result was released: D D M M Y Y Y Y
Y N Specimen included Time result was released: H H H H
Call to ward to determine inclusion criteria and collection method: Name of calling physician:
Time of call to ward D D M M Y Y Y Y H H H H
Name of ward staff who provided data CLINICAL OUTCOME at 72 hours after positive culture
Time of Collection D D M M Y Y Y Y H H H H
TIme rec'd in microbiology lab (not lab office):D D M M Y Y Y Y H H H H UTI treated
Method of Collection Midstream (non-catheterized) UTI untreated
In/out Catheter (non-catheterized) ASB treated
Indwelling Catheter (catheterized) ASB untreated
If included, assign study number: Study Number Bacteremia
Results of Randomization: (stratified by collection method) Collection of positive blood culture D D M M Y Y Y Y
Restricted reporting Standard reporting  H H H H
Time of Report: D D M M Y Y Y Y H H H H Preliminary positive blood culture D D M M Y Y Y Y
DEMOGRAPHICS H H H H
MCP:     Identification of positive blood culture
DOB: D D M M Y Y Y Y AGE: Gender M F
Ward  Systemic Inflammatory Response Criteria
Body temperature > 38.3°C or < 36°CD D M M Y Y Y Y
Reason for Admission: Pulse > 90/min D D M M Y Y Y Y
CULTURE RESULTS Respirations > 20/min D D M M Y Y Y Y
Bacterial ID:  WBC count >12,000 or < 4,000 D D M M Y Y Y Y
Bacterial Count: Altered mental status D D M M Y Y Y Y
CLINICAL INFORMATION Significant edema or positive fluid balanceD D M M Y Y Y Y
UTI Diagnosis is based on assessment by investigator Hyperglycemia (w/o diabetes) D D M M Y Y Y Y
CDC Criteria (Catheter & Non-Catheter)
Patient has at least one of the following signs or symptoms ADVERSE EFFECTS at 7 days after positive culture
Fever (≥ 38 °C)
Suprapubic Tenderness New symptom after study inclusion until 7 days
CVA Pain/Tenderness Symptom 1 
Frequency Onset D D M M Y Y Y Y
Urgency H H H H
Dysuria Details
Patient true diagnosis assessed by investigator:
Urinary Tract Infection (UTI)
Asymptomatic Bacteriuria (ASB)  
ANTIBIOTIC TREATMENT 
After urine collection: Symptom 2 
Drug Dosage Route Frequency Duration Onset D D M M Y Y Y Y
H H H H
Details
Date of first dose: D D M M Y Y Y Y
Time of first dose:  - 
After ID Reported Symptom 3 
Drug Dosage Route Frequency Duration Onset D D M M Y Y Y Y
Details H H H H
Date of first dose: D D M M Y Y Y Y
Time of first dose:  - 
After Susceptibility Reported Unscheduled visit D D M M Y Y Y Y
Drug Dosage Route Frequency Duration Details
Date of first dose: D D M M Y Y Y Y











































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix B: Antibiotics Used 
 
Table 10: All Antibiotics Used for Treatment 
 
Standard Report 
Drug Frequency Percent Cumulative Percent 
Amoxicillin/Clavulanate 1 2.2 2.2 
Ampicillin 1 2.2 4.4 
Ceftriaxone 6 13.0 17.4 
Ciprofloxacin 12 26.1 43.5 
Nitrofurantoin 7 15.2 58.7 
None + N/A 12 26.0 84.7 
Pip/Tazo 3 6.5 91.4 
Septra DS 4 8.8 100.0 
Total 46 100 100.0 
Modified Report 
Drug Frequency Percent Cumulative Percent 
Amoxicillin 2 3.7 3.7 
Amoxicillin/Clavanulate 1 1.9 5.6 
Azithromycin 1 1.9 7.5 
Caspofungin 1 1.9 9.4 
Ceftriaxone 5 9.3 18.7 
Ciprofloxacin 8 14.8 33.5 
Clindamycin 1 1.9 35.4 
Ertapenem 1 1.9 37.3 
Gentamicin 1 1.9 39.2 
Nitrofurantoin  7 13.0 52.2 
None + N/A 17 31.1 83.3 
Piperacillin/Tazobactam 3 5.6 88.9 
Septra 2 3.7 92.6 
Septra DS 4 7.4 100.0 
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